Navigation Links
Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Date:4/25/2008

percentages in a 4-week study that are similar to HCV protease inhibitors and has an encouraging short-term clinical safety profile. Longer-term studies of R7128 with Pegasys plus Copegus are needed to provide additional information about its potential to improve sustained virologic response (SVR) rates for HCV patients."

R7128 4-week Combination Study Overview

The 4-week Phase 1 combination clinical trial was a multiple center, observer-blinded, randomized and placebo-controlled study that was conducted in 50 treatment-naive patients chronically infected with HCV genotype 1. The primary objective was to assess the safety, tolerability and pharmacokinetics of R7128 in combination with Pegasys plus Copegus. The secondary objective was to evaluate the change in HCV RNA after 4 weeks of treatment.

The study investigated two oral dose levels of R7128, 500mg and 1500mg, each administered twice-daily (BID) with once-weekly injections of Pegasys plus Copegus BID. Each cohort of 25 patients was comprised of 20 patients receiving R7128 and 5 patients receiving placebo with Pegasys plus Copegus.

Antiviral Activity Summary

Placebo + R7128 500mg + R7128 1500mg +

Pegasys plus Pegasys plus Pegasys plus

Copegus Copegus Copegus

(n=10) (n=20) (n=20)

Mean Decrease in

HCV RNA (log10 IU/mL)

at 4 Weeks -2.95 -3.82 -5.12

Percentage of Patients

with Undetectable

HCV RNA (<15 IU/mL)

at 4 Weeks (RVR) 10% 30% 85%

Potent antiviral activity was demonstrated following 4 weeks of treatment with R7128 1500mg BID with Pegasys plus Copegus. These patients achieved a mean 5.12 log10 IU/mL decrease in HCV RNA and 85% (17 of 20) had undetectable
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
2. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
3. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
6. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
7. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
8. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
9. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
10. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
11. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  VentiRx Pharmaceuticals, Inc., a clinical stage ... commercialization of novel Toll-like receptor 8 (TLR8) ... and clinical activities at the company including ... clinical trials and future clinical development efforts. ... Officer Robert Hershberg , M.D., Ph.D. ...
(Date:9/2/2014)... Sept. 2, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... products marketed as XIAFLEX ® in the U.S. and ... President, Tom Wegman , will present at the following ... Rodman & Renshaw 16 th Annual ... Tuesday, September 9, 2014 at 9:10 a.m. EDT ...
(Date:9/2/2014)... OAKS, Calif. , Sept. 2, 2014 ... today announced the submission of a Marketing ... Agency (EMA) via the centralized procedure for ... of adults with melanoma that is regionally ... oncolytic immunotherapy administered as an intralesional injection ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 6
(Date:9/2/2014)... York (PRWEB) September 02, 2014 - ... defined as a class of diagnostic test that analyzes ... The nucleic acids and proteins that belong to individual ... therapy, health condition, or risk of developing a specific ... better known as (MDx) evaluating the new class of ...
(Date:9/2/2014)... A New York City based company ... simple, yet revolutionary, product that will have ... health care costs for Americans. , REMIND-A-CAP™ ... puts control in the user's hands. It's a simple ... next date of intake by simply turning a knob. ...
(Date:9/2/2014)... may help scientists learn why patients with cystic fibrosis ... their lungs are relatively healthy. , The researchers ... treat pulmonary hypertension and Viagra for erectile dysfunction ... help them identify the root of the blood vessel ... , "We want to understand why these patients have ...
(Date:9/2/2014)... there might be a new salve to dominate medicine cabinets ... lowly salamander. Salamanders may not be the cuddliest of animals, ... of seriously damaged body parts. Now, a new report published ... Journal , identifies a small protein (called a "peptide") ... to unlocking the secret of this amazing wound healing trick ...
(Date:9/2/2014)... of Nuclear Medicine and Molecular Imaging (SNMMI) is pleased ... Fellowship. This two-year fellowship, founded in 2008 by the ... Kanji Torizuka, MD, PhD, is designed to provide extensive ... and molecular imaging for Japanese physicians in the early ... proud to sponsor the Wagner-Torizuka Fellowship. This program honors ...
Breaking Medicine News(10 mins):Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 2Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 3Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 4Health News:REMIND-A-CAP™ , A New York City Based Company Invents Groundbreaking Prescription Cap to Curb Non-Adherence 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4Health News:Salamander skin peptide promotes quick and effective wound healing in mice 2Health News:SNMMI 2014-2016 Wagner-Torizuka Fellowship recipients announced 2
... moms have lower rates of depression than their stay-at-home counterparts, ... at greater risk for depression, suggests new research to be ... Association. The study shows that working mothers who ... be blended with relative ease showed higher levels of depression ...
... Paper money worldwide is contaminated with the potentially toxic chemical ... is used to make some plastics and consumer products such ... that BPA is an endocrine disruptor, which means that it ... to a number of health problems. Researchers analyzed 156 ...
... Aug. 19 (HealthDay News) -- Some patients do dream while ... still have a form of consciousness about themselves and the ... electroencephalography (EEG) to compare the structure of sleep in 11 ... five in a vegetative state (unresponsive wakefulness). "We used ...
... can reduce the risk of strokes as well as heart ... System neurologists caution that statins may not be appropriate for ... The article, by Dr. Murray Flaster and colleagues, appears in ... Neurotherapeutics . , A landmark 2006 study known as SPARCL, ...
... , THURSDAY, Aug. 18 (HealthDay News) -- A calcium ... to provide insight into the likelihood that certain patients at ... or stroke, researchers say. The test to detect ... take cholesterol-lowering drugs to reduce their cardiovascular risks, the study ...
... For better or for worse, in sickness and in ... associates marriage with reducing unhealthy habits such as smoking, ... However, new research is emerging that suggests married straight ... intimate relationships may pick up each other,s unhealthy habits ...
Cached Medicine News:Health News:Less depression for working moms who expect that they 'can't do it all' 2Health News:Paper Money Worldwide Tainted With BPA: Study 2Health News:People Appear to Dream While in Minimally Conscious State 2Health News:Cholesterial drugs can reduce the risk of stroke, but aren't for everyone 2Health News:Test for Calcium Buildup May Spot Heart Attack, Stroke Risk 2Health News:Long-term, intimate partnerships can promote unhealthy habits 2Health News:Long-term, intimate partnerships can promote unhealthy habits 3
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Ultra HDL (UHDL) assay is used for the quantitation of high density lipoprotein (HDL) cholesterol in human serum or plasma....
... A histological embedment block ... This file system incorporates ... embedment block protection, simplified ... error and facilitation of ...
... The first instrumentation ... efficiently manage the ... Proven technology automatically ... collates cassettes sequentially. ...
Medicine Products: